Abstract -L-a-glycerophosphate oxidase (GlpO) plays a central role in virulence of Mycoplasma mycoides subsp. mycoides SC, a severe bacterial pathogen causing contagious bovine pleuropneumonia (CBPP). It is involved in production and translocation of toxic H 2 O 2 into the host cell, causing inflammation and cell death. The binding site on GlpO for the cofactor flavin adenine dinucleotide (FAD) has been identified as Gly 12 ÀGly 13 ÀGly 14 ÀIle 15 ÀIle 16 ÀGly 17 . Recombinant GlpO lacking these six amino acids (GlpODFAD) was unable to bind FAD and was also devoid of glycerophosphate oxidase activity, in contrast to non-modified recombinant GlpO that binds FAD and is enzymatically active. Polyclonal monospecific antibodies directed against GlpODFAD, similarly to anti-GlpO antibodies, neutralised H 2 O 2 production of M. mycoides subsp. mycoides SC grown in the presence of glycerol, as well as cytotoxicity towards embryonic calf nasal epithelial (ECaNEp) cells. The FAD-binding site of GlpO is therefore suggested as a valuable target site for the future construction of deletion mutants to yield attenuated live vaccines of M. mycoides subsp. mycoides SC necessary to efficiently combat CBPP.
INTRODUCTION
Glycerol metabolism is described to play a central role in virulence of Mycoplasma mycoides subsp. mycoides SC, the etiological agent of contagious bovine pleuropneumonia (CBPP) [4, 13, 14, 20] , as well as in Mycoplasma pneumoniae [9] . Glycerol at physiological concentrations is incorporated and phosphorylated to obtain a-glycerol-3-phosphate (G3P) by M. mycoides subsp. mycoides SC via the highly active ATP-dependent glycerol transporter system GtsABC and then further metabolised to dihydroxyacetone phosphate (DHAP) in the presence of oxygen by the L-a-glycerophosphate oxidase (GlpO, also named a-glycerol-3-phosphate oxidase) with the release of the highly toxic compound hydrogen peroxide H 2 O 2 [20] . Scattered electron microscopy and Triton X-114 partitioning revealed GlpO to be membrane-located in M. mycoides subsp. mycoides SC with a significant part of the protein being surface-exposed [13] , which explains the fact that the mycoplasma is able to release significant amounts of H 2 O 2 into the growth medium.
Using a cell culture infection model for M. mycoides subsp. mycoides SC it was shown that H 2 O 2 is not only released by the mycoplasma This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any noncommercial medium, provided the original work is properly cited.
but directly translocated into the eukaryotic host cells causing cytotoxicity and cell death [13] . M. mycoides subsp. mycoides SC strains generally possess the glycerol ABC transporter GtsABC for the assimilation of glycerol with the exception of strains from recent European outbreaks (period 1980-1999) producing significantly lower amounts of H 2 O 2 [8, 20] and showing a very low cytotoxicity level towards eukaryotic host cells in the presence of glycerol compared to most other strains [4, 13] . Blocking the L-a-glycerophosphate oxidase GlpO by monospecific anti-GlpO antibodies hampers the production and release of H 2 O 2 and concomitantly inhibits cytotoxicity of M. mycoides subsp. mycoides SC towards embryonic calf nasal epithelial (ECaNEp) cells [13] . These results indicate that GlpO may act as a useful antigen target to induce protective immunity against CBPP.
Furthermore, since GlpO-promoted H 2 O 2 production is a central virulence attribute of M. mycoides subsp. mycoides SC, the glpO gene represents an ideal target for mutations in order to better attenuate vaccine strains, whose residual virulence is of concern. In this respect, it has to be mentioned that the live vaccine strains T1/44 and T1/Sm are currently used to vaccinate against CBPP [18] . However, both vaccines have been shown to contain a fully active glycerol transport system GtsABC and an enzymatically active L-a-glycerophosphate oxidase GlpO, which results in the release of significant amounts of H 2 O 2 in the presence of physiological concentrations of glycerol [4, 21] and cytotoxicity against ECaNEp cells [4] . This feature might be the cause of unwanted side reactions encountered with these vaccines [17] and of CBPP elicitation in cattle upon inoculation of T1-derived vaccines via the endobronchial route [11] .
In the current work, we studied the basic, structural and functional features of GlpO of M. mycoides subsp. mycoides SC with the aim of identifying mutation sites in the glpO gene for future live vaccine development. In this view, the mutations should result in (i) loss of H 2 O 2 -producing enzymatic activity; (ii) attenuation of currently used vaccines; and (iii) preservation of the antigenic properties of GlpO required to elicit neutralising antibodies like those induced by native GlpO [13] . GlpO (EC 1.1.3.21) is an enzyme that belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of the donor with oxygen as the acceptor. It employs one cofactor, flavin adenine dinucleotide (FAD). In biochemistry, FAD is a redox cofactor involved in several important metabolic reactions. FAD can exist in two different redox states and its biochemical role usually involves alternating between these two states. FAD can be reduced to FADH 2 , whereby it accepts two hydrogen atoms. FADH 2 is an energy-carrying molecule, and the reduced coenzyme can be utilised as a substrate for oxidative phosphorylation. FADH 2 is re-oxidised to FAD, which makes it possible to produce two moles of the universal energy carrier ATP. The ADP portion of FAD interacts mostly via residues from the first b-stranda-helix-b-strand (bab) fold in the N-terminal portion of GlpO, which includes the Gly-X-Gly-X-X-Gly fingerprint that interacts with the diphosphate moiety of FAD [7] .
The present study investigated the function of recombinant GlpO from M. mycoides subsp. mycoides SC, determining the FAD-binding site and the potential of mutant GlpODFAD, i.e., the recombinant GlpO without the FAD-binding site Gly 12 -Gly 13 -Gly 14 [15] was used for expression of recombinant N-and C-terminal polyhistidine fusion proteins.
ECaNEp cells
ECaNEp cells were prepared from foetuses obtained from a local abattoir and were maintained in minimal essential medium (MEM)-Earle medium supplemented with 7% foetal calf serum and penicillin (100 IU/mL) in 24-well microtiter plates and used at a confluent density of 2 · 10 5 cells per well, at 37°C in a humidified 5% CO 2 atmosphere [13] . Foetal calf serum and cell culture media were purchased from Seromed (Biochrom, Munich, Germany). The cells were routinely screened for contamination by mycoplasmas using PCR or for contamination by bovine viral diarrhoea virus using immunostaining [16] .
Bioinformatics
Comparison of the GlpO protein sequence of strain Afadé with the EMBL/GenBank database was performed using the BLAST program blastp [1] . The PSIPRED Protein Structure Prediction Server v2.6 [12] was used to predict the secondary structure of GlpO of strain Afadé.
Since no 3D structures are annotated in the 3D databases for GlpO of M. mycoides subsp. mycoides SC, a search for 3D domains for bacterial GlpO sequences within available sequences from the NCBI site was performed. Among the 14 GlpO structures found, L-a-glycerophosphate oxidase 2RGH:A from Streptococcus [7] was selected for comparison with the GlpO of M. mycoides subsp. mycoides SC. The 3D-Mol Viewer software from the Vector NTI Advance 10.3.0 package (Invitrogen AG, Basel, Switzerland) was used to display the 3D protein structure model of 2RGH:A with its FAD molecule. The SWISS-MODEL software [2] , accessible via the ExPASy web server, was used to display GlpO of M. mycoides subsp. mycoides SC taking 2RGH:A from Streptococcus as the template.
Cloning and expression of recombinant proteins
The glpO gene of M. mycoides subsp. mycoides strain Afadé was first amplified with the primers Afadé_EcoRI and MmmSC_GlpO_BamHI (Tab. I) containing the restriction sites for EcoRI and BamHI, respectively. As a template for PCR amplification, plasmid pETHIS-1::glpO containing mutagenised TGG Trp codons in the glpO gene [13] was used. The pETHIS-1 vector was amplified with the primers pETHIS-1_EcoRI and pETHIS-1_BamHI (Tab. I) to give the linearised vector pETHIS-1m harbouring EcoRI and BamHI restriction sites. This procedure was used to create GlpO fusion with a polyhistidine tail at the C-terminus only. Purified recombinant GlpO carrying the 10xHis-tagged C-terminus was shown to be enzymatically more active under the in vitro conditions used in this study compared to GlpO with polyhistidine tags at both N-terminal and C-terminal ends.
The codons for the putative FAD-binding site Gly 12 -Gly 13 -Gly 14 -Ile 15 -Ile 16 -Gly 17 on glpO were removed using the overlap extension-PCR method [5] to obtain the glpODFAD gene. The codons for the putative FAD-binding site located at nucleotides (nt) 34-51 downstream of the ATG start codon of the glpO sequence of strain Afadé with EMBL/ GenBank accession number AJ581566 were removed subsequently with (i) primer pair MmmSC_glpO_ FAD1F and MmmSC_glpO_FAD1R (Tab. I) to remove bases 34-39 coding for Gly 12 -Gly 13 , followed by (ii) primer pair MmmSC_glpO_FAD2F and MmmSC_glpO_FAD2R (Tab. I) to remove bases 40-45 coding for Gly 14 -Ile 15 , and (iii) primer pair MmmSC_glpO_FAD3F and MmmSC_glpO_ FAD3R (Tab. I) to remove bases 46-51 coding for Ile 16 -Gly 17 . The products were cloned into pETHIS-1m by flanking EcoRI and BamHI cleavage sites. The constructs were analysed by DNA sequencing and the final clone was introduced into E. coli BL21(DE3) for expression. The expression of the cloned glpODFAD gene was induced by the addition of 1 mM IPTG at mid-exponential phase and further incubation for 4 h at 30°C. Following induction, the polyhistidine-tailed fusion protein GlpODFAD was purified via Ni 2+ chelation chromatography on a Ni-NTA column under denaturing conditions as described previously for other proteins [15, 19] . The fractions were dialysed and analysed on SDS-10% polyacrylamide gels.
Immunoblot analysis with mouse anti-His antibody (GE Healthcare, Otelfingen, Switzerland) (at a dilution of 1:3000) was carried out by standard methods [3] , using SDS-10% polyacrylamide gels for separation of the proteins, which were blotted onto nitrocellulose membranes. Phosphatase-labelled conjugate goat anti-mouse immunoglobulin G (heavy plus light chains) (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) at a dilution of 1:2000 was used for the visualisation of recombinant, polyhistidine-tailed proteins on blots.
In vitro activity assay
Both recombinant, polyhistidine-tailed proteins GlpO and GlpODFAD were also purified under 4 , 300 mM NaCl, 1 mM imidazole, pH 6.5) followed by sonification in a Branson Sonifier and binding for 1 h at 4°C to Ni-NTA beads. The beads were then washed with buffer B and eluted with buffer D. The fractions were analysed on SDS-10% polyacrylamide gels. The activities of purified recombinant proteins GlpO and GlpODFAD were measured by their ability to produce H 2 O 2 in the presence of glycerol. The activity assay was performed in the presence of filter-sterilised incubation buffer (67.7 mM HEPES, 140 mM NaCl, 7 mM MgCl 2 , pH 7.3) supplemented with 9 mM ATP, 65 nM FAD and 6 mM a-glycerol-3-phosphate (G3P), to which recombinant GlpO or recombinant GlpODFAD was added at a final 20 lg/mL concentration. The production of H 2 O 2 was measured with the peroxide test (Merck KgaA, Darmstadt, Germany) as described previously [20] .
Fluorescence measurements
Fluorescence excitation and emission spectra of the proteins was measured with a Perkin-Elmer LS50 dual wavelength fluorescence spectrophotometer. The emission spectrum (370-600 nm) at an excitation wavelength of 350 nm and the excitation spectrum (250-410 nm) at an emission wavelength of 430 nm were recorded as described previously [6] .
Sera, polyclonal antibodies and immunoglobulin purification
Immune sera directed against recombinant GlpO or GlpODFAD were obtained by subcutaneous immunisation of rabbits with 80 lg of purified recombinant polyhistidine-tailed proteins in 500 lL of phosphate-buffered saline (PBS) buffer (50 mM Na 2 HPO 4 /NaH 2 PO 4 , 140 mM NaCl, pH 8.0), mixed with 500 lL of Adjuvant 10 (Gerbu Biotechnik GmBH, Gaiberg, Germany). Primary immunisation was followed by booster injections with 80 lg of the respective protein 2 and 4 weeks later. The rabbits were bled 21 days after the last booster immunisation. Antisera were prepared from the blood samples and stored at À20°C.
Immunoglobulin G (IgG) fractions from decomplemented rabbit anti-GlpO and anti-GlpODFAD sera were purified with the HiTrap Protein G kit (Amersham Pharmacia Biotech, Uppsala, Sweden) as directed by the manufacturer. Protein concentrations were determined using a NanoDrop ND-1000 spectrophotometer (Witec AG, Littau, Switzerland).
Quantification of H 2 O 2 and inhibition assay
To measure H 2 O 2 production, strains of M. mycoides subsp. mycoides SC were grown in mycoplasma culture medium for 3 days at 37°C to a density of approximately 5 · 10 8 cells/mL. The culture was centrifuged at 8 000 · g for 10 min at 4°C, washed once in incubation buffer, resuspended in prewarmed incubation buffer at 37°C at a density of 10 9 cells/mL, portioned in aliquots of 1 mL, and incubated at 37°C for 1 h. To induce H 2 O 2 production, glycerol was added to the mycoplasma suspensions at a final concentration of 100 lM, representing the physiological concentration of glycerol in bovine serum. The production of H 2 O 2 was measured with the peroxide test (Merck KgaA) as described previously [20] at time zero and 1, 2, 5, 10, 20 and 40 min after the addition of glycerol. In order to measure the inhibitory potential of anti-GlpO or anti-GlpODFAD antibodies, mycoplasmas were pretreated with IgG preparations of either anti-GlpO or anti-GlpODFAD antiserum at concentrations of 10 lg/mL for 30 min at 37°C, followed by two washes with PBS buffer.
Detection of translocation of H 2 O 2 from infecting mycoplasmas into ECaNEp cells
To monitor intracellular H 2 O 2 and accompanying reactive oxygen species (ROS) in ECaNEp cells, the formation of dichlorofluorescein derivatives after cleavage of the ester groups of nonfluorescent 5 (and 6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate-acetyl ester (CM-H 2 DCFDA; Molecular Probes, Eugene, OR, USA) by H 2 O 2 -dependent oxidation was measured as already described [13] . The ECaNEp cells were incubated for 1 h with 10 lM CM-H 2 DCFDA and washed once with MEM-Earle medium. Cells were then infected with M. mycoides subsp. mycoides SC strain Afadé at a multiplicity of infection (MOI) of 500 mycoplasmas per cell in the presence or absence of 100 lM glycerol. To assess blocking of the GlpO activity, M. mycoides subsp. mycoides SC cells were pre-treated with anti-GlpO or anti-GlpODFAD IgG at 8 to 28 lg/mL. Intracellular H 2 O 2 was monitored 20 min after infection with mycoplasmas by fluorescence microscopy using a Nikon Eclipse TE 300 microscope. Note that all steps involving CM-H 2 DCFDA, including handling of this chemical, were performed in the dark.
RESULTS

FAD-binding site Gly-X-Gly-X-X-Gly of GlpO
The results obtained with the BLAST program blastp showed that the 387-aa GlpO of M. mycoides subsp. mycoides SC strain Afadé (EMBL/GenBank accession number CAE46342) has strong homologies to several bacterial glycerol-3-phosphate oxidases and glycerol-3-phosphate dehydrogenases. In some cases, these similar proteins are larger than 450 aa in length and the GlpO-homologous portions reside in their N-termini (not shown).
The secondary structure prediction of GlpO of strain Afadé indicates the presence of a bab fold in its N-terminal portion, which includes the Gly-Gly-Gly-Ile-Ile-Gly fingerprint that is assumed to interact with the diphosphate moiety of FAD (Fig. 1) . A comparison with protein 2RGH:A, the L-a-glycerophosphate oxidase from Streptococcus [7] , demonstrated the presence of two putative G3P-binding sites also in GlpO from M. mycoides subsp. mycoides SC. They are located in the region spanning aa residues 310-350, close to the C-terminus (Fig. 1) .
Protein 2RGH:A, whose 3D structure is known, was chosen as a model to envisage the possible 3D structure of GlpO from M. mycoides subsp. mycoides SC. 2RGH:A showed the three Gly residues in the Gly-X-Gly-X-XGly fingerprint (in this case Gly 39 -Gly 40 -Gly 41 -Ile 42 -Thr 43 -Gly 44 ) in a bab fold in the vicinity of the diphosphate moiety of FAD ( Fig. 2A) , which corresponds to the putative FAD-binding site Gly 12 -Gly 13 -Gly 14 -Ile 15 -Ile 16 -Gly 17 in the GlpO of M. mycoides subsp. mycoides SC strain Afadé (Fig. 2B ).
Structural properties and enzymatic activity of recombinant GlpO and GlpODFAD
Immunoblot analysis of recombinant proteins GlpO and GlpODFAD, both carrying a 10xHis-tagged C-terminus, with anti-His antibodies revealed two protein bands of 45 and 90 kDa for GlpO and one single protein band of 44 kDa for GlpODFAD (Fig. 3A) . Both polyclonal monospecific anti-recombinant GlpO and GlpODFAD sera strongly reacted with a 43-kDa protein and poorly reacted with 85-and 125-kDa proteins from total antigen of M. mycoides subsp. mycoides SC strain Afadé (Fig. 3B) . To test the activity of both enzymes, recombinant proteins GlpO and GlpODFAD were purified under native conditions and tested for their functional and enzymatic activities. A final concentration of 20 lg/mL for both recombinant proteins was used in the assays. Under in vitro conditions, recombinant GlpO of M. mycoides subsp. mycoides SC oxidised G3P with release of 2 lg/mL H 2 O 2 into the assay solution after 10 min incubation and 10 lg/mL H 2 O 2 after 40 min incubation. In contrast, recombinant GlpODFAD showed no release of H 2 O 2 into the assay solution.
Spectroscopic analysis of GlpO and GlpODFAD
It was observed that cell lysates of GlpOproducing E. coli had a yellowish appearance, whereas cell lysates with the protein GlpOD-FAD had a whitish appearance, like E. coli BL21(DE3) harbouring vector pETHIS-1 without insert. This indicates that cell lysates with recombinant GlpO contained protein-bound flavin (i.e. bound FAD), whereas GlpODFAD did not bind FAD.
In order to confirm this, fluorescence spectra of the two recombinant proteins GlpO and GlpODFAD were measured and compared with the spectra of an FAD solution, the latter displaying an emission maximum at 525 nm. The fluorescence spectra of recombinant GlpO-samples displayed the typical protein-derived excitation maximum at 280 nm and also showed an emission maximum at 525 nm (Fig. 4) , indicating that recombinant GlpO contained bound FAD that must have been acquired during overexpression in E. coli. In contrast, fluorescent spectroscopic analysis of recombinant GlpODFAD displayed solely an excitation maximum at 280 nm and no peak visible at 525 nm in the emission spectrum, showing that this recombinant protein did not contain bound FAD (Fig. 4) . These results indicate that recombinant GlpODFAD lacking the putative FAD-binding site Gly 12 -Gly 13 -Gly 14 -Ile 15 -Ile 16 -Gly 17 was unable to acquire and bind the cofactor FAD when expressed in E. coli, hence explaining why it is enzymatically inactive.
Neutralising activity of anti-GlpODFAD antibodies
With respect to future vaccine design, it appears highly desirable to use enzymatically inactive GlpO eliciting antibodies in immunised animals able, like those directed against native GlpO [13] , to neutralise GlpO and thereby obliterating the cytotoxic effect of M. mycoides subsp. mycoides SC. The neutralising activity of rabbit antibodies that were induced by immunisation with recombinant GlpODFAD was therefore assessed.
As observed with rabbit anti-GlpO [13] , decomplemented rabbit anti-GlpODFAD serum and protein G-purified IgG prepared thereof were shown to specifically block the release of H 2 O 2 by M. mycoides subsp. mycoides SC strain Afadé grown in liquid medium supplemented with 100 lM glycerol. Pre-immune serum or IgG of the unvaccinated rabbit had no inhibitory effect. Consequently, the GlpOD-FAD protein lacking the FAD-binding site and the native GlpO have similar capacities to induce GlpO-neutralising antibodies.
In order to evaluate whether anti-GlpOD-FAD antibodies are also able to neutralise translocation of H 2 O 2 and the accompanying oxygen radicals from M. mycoides subsp. mycoides SC into ECaNEp cells, and the resulting cytotoxic effects, ECaNEp cells were pre-treated with CM-H 2 DCFDA to detect intracellular oxidation of this compound by fluorescence microscopy. Infection with the African M. mycoides subsp. mycoides SC field strain Afadé produced a strong induction of fluorescence in ECaNEp cells 20 min after the addition of glycerol, reflecting the presence of intracellular H 2 O 2 , an event followed by cell death. No fluorescence was detected in the control experiment where ECaNEp cells were infected with the Afadé strain without the addition of glycerol (Fig. 5) . Intracellular oxidation of CM-H 2 DCFDA in ECaNEp cells as visualised by fluorescence was inhibited when infecting M. mycoides subsp. mycoides SC were pre-treated with antibodies directed either against GlpO (Fig. 5C ) or against GlpODFAD (Fig. 5D ). This showed that GlpODFAD is able to induce antibodies that prevent H 2 O 2 translocation from infecting M. mycoides subsp. mycoides SC to the host cells.
DISCUSSION
With the aim of designing new live vaccines against CBPP using specific, targeted, attenuating mutations in the genome of M. mycoides subsp. mycoides SC, we investigated the role of the FAD-binding site of the L-a-glycerophosphate oxidase GlpO, a central enzyme for the virulence of this pathogen [4, 13, 14] . Spectroscopic analysis revealed that the modified recombinant GlpODFAD -the GlpO protein-mutant whose FAD-binding site was knocked out by recombinant gene technologywas devoid of bound FAD while the intact recombinant GlpO did contain bound FAD. It is interesting to note at this point that purified recombinant GlpO, in contrast to GlpODFAD, showed two protein bands on SDS-polyacrylamide gels and immunoblots, the larger band being attributed to the formation of a dimeric aggregate of GlpO, in accordance with the finding that this oxidase is a dimeric protein in other organisms [6, 7] . The observation that GlpOD-FAD is present uniquely as a monomer on immunoblots suggests that the lack of the FAD-binding site (or the failure of binding FAD) also changed structural properties of this protein. Furthermore, the FAD-binding site of GlpO was demonstrated to play a central role in the enzymatic activity of the oxidase, as shown by the inability of GlpODFAD to oxidise a-glycerol-3-phosphate (G3P) and to produce toxic H 2 O 2 .
Antibodies that were raised in rabbits against purified recombinant GlpODFAD, like antiGlpO antibodies, were able to (i) recognise three bands (representing monomer, dimer and a possible trimer on immunoblots) of GlpO from total proteins of M. mycoides subsp. mycoides SC; (ii) block the H 2 O 2 production of M. mycoides subsp. mycoides SC metabolising glycerol; and (iii) neutralise the resulting cytotoxicity towards host cells in an in vitro assay.
Taken together, these results suggest that the removal of the FAD-binding site from the glpO gene of M. mycoides subsp. mycoides SC provides an ideal means to attenuate cytotoxicity of future live vaccines, with preserved capacity to elicit efficient GlpO-neutralising antibodies in the host. In order to replace the glpO wild type gene in the chromosome of M. mycoides subsp. mycoides SC with the glpODFAD allele for creation of a targeted deletion mutant, novel, more powerful methods for allelic replacement still need to be developed since this organism does not seem to be particularly apt to homologous recombination [10] .
